RVTY צמיחה צפויה ברווח נקי למניה השנה Revvity, Inc.

Revvity, Inc. (RVTY) leverages manufacturing capacities in Europe and the US to supply equipment to global pharmaceutical companies. The company maintains its scientific leadership through the implementation of AI screening and genomic analysis. The annual EPS trend, where the current status is 7.20, clearly demonstrates the business's resilience to geopolitical risks and data exchange restrictions with China.

This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of capital generation efficiency relative to inflationary risks. By analyzing the annual EPS growth rate, investors determine the asset's value potential, which for Revvity, Inc. (RVTY) is supported by a steady cash flow from the sale of laboratory systems and consumables.